Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Tedroff

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Nordisk Medicin|March 14, 1998
[How can PET scan be used in Parkinson disease?]J Tedroff
Acta Neurologica Scandinavica. Supplementum|January 1, 1989
Brain dopaminergic mechanisms in Parkinson's disease evaluated by positron emission tomographyS M Aquilonius, B Långström, J Tedroff
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 1998
Reversible chorea in primary antiphospholipid syndromeJ Sundén-Cullberg, J Tedroff, S M Aquilonius
Acta Radiologica. Supplementum|January 1, 1991
Positron emission tomography and the striatal dopaminergic terminals in monkeys and in manS M Aquilonius, P Hartvig, B Långström, et al.
Neurology|October 26, 1999
Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's diseaseJ Tedroff, A Ekesbo, C Sonesson, et al.
Annals of Neurology|March 1, 1997
Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's diseaseR Torstenson, P Hartvig, B Långström, et al.
European Journal of Clinical Pharmacology|January 1, 1990
Pharmacokinetics and effects of levodopa in advanced Parkinson's diseaseE Bredberg, J Tedroff, S M Aquilonius, et al.
Annals of Neurology|September 11, 1999
Regulation of dopaminergic activity in early Parkinson's diseaseJ Tedroff, A Ekesbo, E Rydin, et al.
Advances in Neurology|January 1, 1996
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degenerationJ Tedroff, S M Aquilonius, P G Hartvig, et al.
Neuroreport|July 28, 1997
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseA Ekesbo, P E Andrén, L M Gunne, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Nordisk Medicin|March 14, 1998
[How can PET scan be used in Parkinson disease?]J Tedroff
Acta Neurologica Scandinavica. Supplementum|January 1, 1989
Brain dopaminergic mechanisms in Parkinson's disease evaluated by positron emission tomographyS M Aquilonius, B Långström, J Tedroff
Movement Disorders : Official Journal of the Movement Disorder Society|February 6, 1998
Reversible chorea in primary antiphospholipid syndromeJ Sundén-Cullberg, J Tedroff, S M Aquilonius
Acta Radiologica. Supplementum|January 1, 1991
Positron emission tomography and the striatal dopaminergic terminals in monkeys and in manS M Aquilonius, P Hartvig, B Långström, et al.
Neurology|October 26, 1999
Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's diseaseJ Tedroff, A Ekesbo, C Sonesson, et al.
Annals of Neurology|March 1, 1997
Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's diseaseR Torstenson, P Hartvig, B Långström, et al.
European Journal of Clinical Pharmacology|January 1, 1990
Pharmacokinetics and effects of levodopa in advanced Parkinson's diseaseE Bredberg, J Tedroff, S M Aquilonius, et al.
Annals of Neurology|September 11, 1999
Regulation of dopaminergic activity in early Parkinson's diseaseJ Tedroff, A Ekesbo, E Rydin, et al.
Advances in Neurology|January 1, 1996
Functional positron emission tomographic studies of striatal dopaminergic activity. Changes induced by drugs and nigrostriatal degenerationJ Tedroff, S M Aquilonius, P G Hartvig, et al.
Neuroreport|July 28, 1997
(-)-OSU 6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's diseaseA Ekesbo, P E Andrén, L M Gunne, et al.
Pageof 5